子宮頸がん治療の世界市場-2022-2029

市場力学

子宮頸がんの有病率の増加、政府の積極的な取り組み、人々の意識向上、標的療法の新たな進歩、薬剤の強力なパイプラインが市場の原動力となっています。

子宮頸がん治療薬のFDA承認の増加は、市場成長の原動力になると予想されます。

2021年9月20日、米国食品医薬品局は、組織因子指向性抗体と微小管阻害剤の結合体であるtisotumab vedotin-tftv（Tivdak, Seagen Inc.）を、化学療法中または後に疾患が進行した再発・転移性子宮頸がん成人患者に対して加速承認しました。2021年10月13日、メルクは、米国食品医薬品局（FDA）が、FDA承認検査により腫瘍がPD-L1（Combined Positive Score[CPS]≧1）を発現する持続・再発・転移性子宮頸がん患者の治療として、ベバシズマブを併用または併用しない化学療法と併用するメルクの抗PD-1療法であるKEYTRUDAを承認したことを公表しました。今回の承認は、KEYTRUDAと化学療法（パクリタキセル＋シスプラチンまたはパクリタキセル＋カルボプラチン）を、ベバシズマブの併用または非併用で同じ化学療法レジメンと比較した第3相KEYNOTE-826試験に基づいています。さらに、国連非感染性疾患タスクフォースの下、7つの国連機関は、子宮頸がんの予防と制御に関する共同プログラムを立ち上げ、世界なリーダーシップと技術支援を提供し、各国政府やパートナーのプログラム構築と持続的な活動を支援しています。このように、上記の記述から、予測期間中に市場が牽引されることが予想されます。

制約事項

治療費の高騰、がん治療に伴う副作用、コストを抑えながら臨床的プロファイルを改善した標的薬の少なさ、新興国でのがん治療に対する認識不足などが、予測期間中の市場の抑制要因になると思われます。

産業分析

子宮頸がん治療市場は、アンメットニーズ、価格分析、サプライチェーン分析、規制分析など、様々な業界要因に基づく市場の詳細な分析を提供します。

世界の子宮頸がん治療市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 子宮頸がん治療薬のFDA承認の増加により、市場成長が見込まれます。
  • 抑制要因
    • 治療費の高騰とがん治療に伴う副作用が市場成長の阻害要因になると予測されます。
  • 機会
  • 影響分析

第5章 産業分析

• ポーターの5つの力
• アンメットニーズ
• サプライチェーン
• プライシング分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• まとめ

第7章 タイプ別

• 扁平上皮癌
• 腺癌
• 腺扁平上皮がん

第8章 治療法別

• 放射線療法
• 化学療法
• 標的治療
• 免疫療法
• 複合療法

第9章 エンドユーザー別

• 病院
• がん専門病院
• 診断センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• F. Hoffmann-LA Roche AG
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Merck & Co., Inc.
• GlaxoSmithKline PLC
• Allergan PLC
• Pfizer, Inc
• Biocon Ltd
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• CooperSurgical, Inc.
• Ethicon, Inc.
• Eli Lilly & Co.
• Teva Pharmaceutical Industries Ltd.
• Varian Medical Systems, Inc.

Market Overview

Cervical Cancer Treatment Market size is projected to reach USD billion by 2029, with growth at a CAGR of 5% during the forecasting period (2022-2029).

The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer begins in the cells of the cervix. Most cervical malignancies are caused by strains of the sexually transmitted pathogen, Human Papillomavirus (HPV). When healthy cells mutate, the illness begins, resulting in uncontrolled cell growth. These cells form a tumor, which spreads to the surrounding tissues. Cervical cancers are divided into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. Adenocarcinomas develop from gland cells, whereas squamous cell carcinomas develop from ectocervical cells. Cancer cells are supposed to mimic squamous cells under the microscope. In adenosquamous carcinomas, squamous cell carcinomas and adenocarcinomas coexist.

Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are all treatments for cervical cancer. Cystoscopy, proctoscopy, anesthesia, and imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), intravenous urography, and Positron Emission Tomography are used to identify cervical cancer (PET scan).

Market Dynamics

The market is driven by increased prevalence of cervical cancer, proactive government initiatives, awareness among people, new advancements in targeted therapies, and a strong pipeline of drugs.

Increasing FDA approvals for cervical cancer drugs is expected to drive market growth.

On September 20, 2021, the Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer who have disease progression during or after chemotherapy. On October 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1)as determined by an FDA-approved test. The approval is based on Phase 3 KEYNOTE-826 trial evaluating KEYTRUDA plus chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) to the same chemotherapy regimens, with or without bevacizumab. Moreover, Seven UN agencies under the United Nations Task Force on non-communicable diseases have established a Joint Programme to prevent and control cervical cancer to provide global leadership and technical assistance to support governments and partners in building and sustaining programs. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High cost of treatment and adverse effects associated with cancer therapy, less number of targeted drugs with improved clinical profile at reduced costs, and lack of awareness of cancer treatment in developing countries are going to restrain the market in the forecast period.

Industry Analysis

The cervical cancer treatment market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Chemotherapy segment is expected to hold the largest market share in the cervical cancer treatment market.

Chemotherapy uses anti-cancer drugs injected into a vein or given by mouth. These drugs enter the bloodstream and can reach all body areas, making this treatment useful for killing cancer cells in most body parts. For some stages of cervical cancer, the preferred treatment is radiation and chemo, called concurrent chemoradiation. The chemo helps the radiation work better. The chemo drugs most often used to treat advanced cervical cancer includes Cisplatin, Carboplatin, Paclitaxel (Taxol), Topotecan, and Gemcitabine (Gemzar). Therefore, it has increased the demand for chemotherapy drugs. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global cervical cancer treatment market.

North America was the dominant region in the global cervical cancer treatment market and is expected to continue its dominance over the forecast period. This growth is attributed to a growing number of patients, increasing market penetration of drugs, and easy accessibility to advanced treatments. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. In contrast, in 2022, about 14,100 new cases of invasive cervical cancer will be diagnosed, and about 4,280 women will die from cervical cancer. Therefore, it has increased the demand for cervical cancer treatment in the region.

Moreover, on September 20, 2021, Seagen Inc. and Genmab A/S granted the U.S. Food and Drug Administration (FDA) approval to TIVDAK (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer who have disease progression during or after chemotherapy. TIVDAK was authorized under the FDA's Accelerated Approval Program based on tumor response and response durability. Continued approval may rely on verifying and describing clinical benefits in confirmatory trials.

Competitive Landscape

Major key players in the cervical cancer treatment market are F. Hoffmann-LA Roche AG, Merck & Co., Inc., GlaxoSmithKline PLC, Allergan PLC, Pfizer, Inc., Biocon Ltd., Bristol-Myers Squibb Company, AstraZeneca PLC, CooperSurgical, Inc., Ethicon, Inc., Eli Lilly & Co., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc.

Pfizer, Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

ZIRABEV (bevacizumab-bvzr): Zirabev has been approved for a number of cancer types and stages, in some cases as a single therapy, and in some cases in combination with other therapies.

Zirabev is approved for:

Colorectal cancer

Non-small cell lung cancer

Glioblastoma

Kidney cancer

Cervical cancer

Ovarian cancer

The global cervical cancer treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing FDA approvals for cervical cancer drugs is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of treatment and adverse effects associated with cancer therapy is expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces
• 5.2. Unmet Needs
• 5.3. Supply Chain
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Squamous Cell Carcinoma*
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Adenocarcinoma
• 7.4. Adenosquamous Carcinoma

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.1.2. Market Attractiveness Index, By Treatment Segment
• 8.2. Radiation Therapy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Chemotherapy
• 8.4. Targeted Therapy
• 8.5. Immunotherapy
• 8.6. Combined Therapy

9. By End user

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.1.2. Market Attractiveness Index, By End user Segment
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Specialized Cancer Centers
• 9.4. Diagnostic Centers
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. F. Hoffmann-LA Roche AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Merck & Co., Inc.
• 12.3. GlaxoSmithKline PLC
• 12.4. Allergan PLC
• 12.5. Pfizer, Inc
• 12.6. Biocon Ltd
• 12.7. Bristol-Myers Squibb Company
• 12.8. AstraZeneca PLC
• 12.9. CooperSurgical, Inc.
• 12.10. Ethicon, Inc.
• 12.11. Eli Lilly & Co.
• 12.12. Teva Pharmaceutical Industries Ltd.
• 12.13. Varian Medical Systems, Inc.